Results 1 to 10 of about 1,727,618 (310)

Human antibodies neutralizing diphtheria toxin in vitro and in vivo. [PDF]

Sci Rep, 2020
Diphtheria is an infectious disease caused by Corynebacterium diphtheriae. The bacterium primarily infects the throat and upper airways and the produced diphtheria toxin (DT), which binds to the elongation factor 2 and blocks protein synthesis, can ...
Wenzel EV, Bosnak M, Tierney R, Schubert M, Brown J, Dübel S, Efstratiou A, Sesardic D, Stickings P, Hust M.   +9 more
europepmc   +2 more sources

Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B. [PDF]

PLoS One, 2016
Botulinum neurotoxins (BoNTs) are counted among the most toxic substances known and are responsible for human botulism, a life-threatening disease characterized by flaccid muscle paralysis that occurs naturally by food poisoning or colonization of the ...
Miethe S, Mazuet C, Liu Y, Tierney R, Rasetti-Escargueil C, Avril A, Frenzel A, Thullier P, Pelat T, Urbain R, Fontayne A, Sesardic D, Hust M, Popoff MR.   +13 more
europepmc   +2 more sources

Defining criteria for broadly neutralizing HIV antibodies [PDF]

Frontiers in Immunology
Over the course of a few years, a small percentage of individuals with HIV-1 develop broadly neutralizing antibodies (bnAbs) capable of neutralizing diverse viruses.
Elizabeth-Sharon David-Fung, Katherine A. Belobrajdic, Jennifer P. Macke, Corey R. Quackenbush, Kumkum Ganguly, Jennifer L. Mamrosh   +5 more
doaj   +2 more sources

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

eLife, 2020
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2.
Yiska Weisblum, Fabian Schmidt, Fengwen Zhang, Justin DaSilva, Daniel Poston, Julio CC Lorenzi, Frauke Muecksch, Magdalena Rutkowska, Hans-Heinrich Hoffmann, Eleftherios Michailidis, Christian Gaebler, Marianna Agudelo, Alice Cho, Zijun Wang, Anna Gazumyan, Melissa Cipolla, Larry Luchsinger, Christopher D Hillyer, Marina Caskey, Davide F Robbiani, Charles M Rice, Michel C Nussenzweig, Theodora Hatziioannou, Paul D Bieniasz   +23 more
doaj   +2 more sources

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Nature, 2020
David D Ho, Manoj S Nair, Yaoxing Huang
exaly   +2 more sources

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Nature, 2021
The SARS-CoV-2 B.1.1.529 (Omicron) variant contains 15 mutations of the receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies requires immediate investigation.
Yunlong Cao, Jing Wang, F. Jian, T. Xiao, Weiliang Song, A. Yisimayi, Weijing Huang, Qian-qian Li, Peng Wang, R. An, Jing Wang, Yao Wang, Xiaowei Niu, Sijie Yang, Huitong Liang, Haiyan Sun, Taojing Li, Yuanling Yu, Qianqian Cui, Shuo Liu, Xiaodong Yang, Shuo Du, Zhiying Zhang, Xiaohua Hao, Fei Shao, R. Jin, Xiangxi Wang, Junyu Xiao, Youchun Wang, X. Xie   +29 more
semanticscholar   +1 more source

Antibody Response to SARS-CoV-2 among COVID-19 Confirmed Cases and Correlates with Neutralizing Assay in a Subgroup of Patients in Delhi National Capital Region, India

Vaccines, 2022
Background: The plaque reduction neutralization test (PRNT) is the gold standard to detect the neutralizing capacity of serum antibodies. Neutralizing antibodies confer protection against further infection.
Puneet Misra, Shashi Kant, Randeep Guleria, Sanjay K. Rai, Abhishek Jaiswal, Suprakash Mandal, Guruprasad R. Medigeshi, Mohammad Ahmad, Anisur Rahman, Meenu Sangral, Kapil Yadav, Mohan Bairwa, Partha Haldar, Parveen Kumar   +13 more
doaj   +1 more source

A new strategy: identification of specific antibodies for neutralizing epitope on SARS-CoV-2 S protein by LC-MS/MS combined with immune repertoire

Molecular Biomedicine, 2022
Although the SARS-CoV-2 vaccine has been widely used worldwide, not all individuals can produce neutralization antibodies, so it is still urgent to find and prepare neutralization antibodies for COVID-19 prevention or treatment. In this study, we created
Meng Yu, Zhu Zhu, Yanqun Wang, Pingzhang Wang, Xiaodong Jia, Jie Wang, Lei Liu, Wanbing Liu, Yaqiong Zheng, Guomei Kou, Weiyan Xu, Jing Huang, Fengmin Lu, Xiajuan Zou, Shangen Zheng, Yinying Lu, Jincun Zhao, Hui Dai, Xiaoyan Qiu   +18 more
doaj   +1 more source

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

Nature Network Boston, 2022
The recent emergence of the SARS-CoV-2 Omicron variant is raising concerns because of its increased transmissibility and its numerous spike mutations, which have the potential to evade neutralizing antibodies elicited by COVID-19 vaccines.
E. Pérez-Then, C. Lucas, V. Monteiro, M. Mirić, V. Brache, L. Cochón, C. Vogels, A. Malik, Elena De la Cruz, A. Jorge, M. De los Santos, P. León, M. Breban, K. Billig, I. Yildirim, C. Pearson, R. Downing, E. Gagnon, A. Muyombwe, J. Razeq, M. Campbell, A. Ko, S. Omer, N. Grubaugh, S. Vermund, A. Iwasaki   +25 more
semanticscholar   +1 more source

Dissecting the human serum antibody response to secondary dengue virus infections. [PDF]

PLoS Neglected Tropical Diseases, 2017
Dengue viruses (DENVs) are mosquito-borne flaviviruses and the causative agents of dengue fever and dengue hemorrhagic fever. As there are four serotypes of DENV (DENV1-4), people can be infected multiple times, each time with a new serotype.
Bhumi Patel, Patti Longo, Michael J Miley, Magelda Montoya, Eva Harris, Aravinda M de Silva   +5 more
doaj   +1 more source